Transitioning toiIntravenous Remodulin (treprostinil sodium) from inhaled iloprost (Ventavis) in patients with pulmonary arterial hypertension: safety, efficacy and treatment satisfaction

Trial Profile

Transitioning toiIntravenous Remodulin (treprostinil sodium) from inhaled iloprost (Ventavis) in patients with pulmonary arterial hypertension: safety, efficacy and treatment satisfaction

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 09 Nov 2007

At a glance

  • Drugs Treprostinil (Primary)
  • Indications Pulmonary hypertension
  • Focus Therapeutic Use
  • Sponsors United Therapeutics Corporation
  • Most Recent Events

    • 09 Nov 2007 Status changed from recruiting to discontinued
    • 17 Apr 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top